Catalyst Wire Dossier Catalyst Wire Dossier

G-202 (Mipsagargin)

Mipsagargin · GenSpera, Inc.
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for G-202 (Mipsagargin), covering 2015-12-10 to 2024-05-21. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma [Phase 2]

See pricing